✦ LIBER ✦

Phase II evaluation of didemnin B in advanced adenocarcinoma of the kidney

✍ Scribed by Sarah A. Taylor; Phyllis Goodman; E. David Crawford; W. J. Stuckey; Ronald L. Stephens; Ellen R. Gaynor

Publisher: Springer US
Year: 1992
Tongue: English
Weight: 130 KB
Volume: 10
Category: Article
ISSN: 0167-6997
DOI: 10.1007/bf01275484

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of didemnin B in advanced

Phase II study of didemnin B in advanced colorectal cancer

✍ Dennie V. Jones; Jaffer A. Ajani; Roxann Blackburn; Karen Daugherty; Bernard Lev 📂 Article 📅 1992 🏛 Springer US 🌐 English ⚖ 222 KB

Phase II trial of didemnin-B in advanced

Phase II trial of didemnin-B in advanced epithelial ovarian cancer

✍ Joanna M. Cain; P. Y. Liu; David E. Alberts; Holly H. Gallion; Leslie Laufman; J 📂 Article 📅 1992 🏛 Springer US 🌐 English ⚖ 157 KB

Phase II trial of Didemnin B in patients

Phase II trial of Didemnin B in patients with advanced renal cell carcinoma

✍ Robert Motzer; Howard Scher; Dean Bajorin; Cora Sternberg; George J. Bosl 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 115 KB

Twenty-three patients with advanced renal cell cancer were treated with Didemnin B. One partial response was achieved (5070) in 21 evaluable patients. An allergic reaction was noted in four patients including one patient with anaphylaxis. Didemnin B is not recommended in the treatment of renal cell

Phase II evaluation of didemnin B in hor

Phase II evaluation of didemnin B in hormonally refractory metastatic prostate cancer

✍ Stephen K. Williamson; Michael K. Wolf; Mario A. Eisenberger; Mark O'Rourke; Wil 📂 Article 📅 1995 🏛 Springer US 🌐 English ⚖ 302 KB

A phase II trial of didemnin B in myelom

A phase II trial of didemnin B in myeloma

✍ Raymond B. Weiss; Bercedis L. Peterson; Steven L. Allen; Scott M. Browning; Davi 📂 Article 📅 1994 🏛 Springer US 🌐 English ⚖ 272 KB

Phase II study of amonafide in advanced

Phase II study of amonafide in advanced pancreatic adenocarcinoma

✍ Kaye Linke; Richard Pazdur; James L. Abbruzzese; Jaffer A. Ajani; Rodger Winn; J 📂 Article 📅 1991 🏛 Springer US 🌐 English ⚖ 262 KB

To determine the efficacy of amonafide in patients with advanced, measurable pancreatic adenocarcinoma, 15 patients previously untreated with chemotherapy were entered on a phase II trial. The starting dose was 400 mg/m 2 administered daily over 1 hr for 5 consecutive days repeated every 3 weeks. Be